This study evaluated the combination of neoadjuvant trastuzumab and lapatinib (and endocrine therapy if hormone receptor-positive) for 12 weeks in 66 patients with stage II-III HER2-positive breast cancer and showed a pCR rate of 27.0%. This evidence concerns the gene ERBB2 and breast carcinoma.